External Committees

Advisory Board

The ICER Advisory Board is comprised of Flagship members of ICER’s Policy Leadership Forum and other select stakeholders. The Advisory Board meets annually with ICER’s Governance Board to provide guidance on ICER’s overall portfolio of activities and strategic plan. The Advisory Board provides perspective and advice to ICER on how it can best fulfill its mission, but the Advisory Board has no direct governance role.

  • Lora Armstrong, PharmD, Vice President, Medical Affairs, CVS Health
  • Carmella Bocchino, RN, MBA, President and CEO, CRB Strategies, LLC
  • Victoria Brown, PharmD, AVP, Clinical Drug Strategy, Humana
  • Ceci Connolly, President and CEO, Alliance of Community Health Plans
  • Patrick Gleason, PharmD, Assistant Vice President, Health Outcomes, Prime Therapeutics
  • Andreas Kuznik, PhD, Executive Director, Health Economics and Outcomes Research, Regeneron Pharmaceuticals, Inc.
  • Kim Le, PharmD, Vice President, National Clinical Pharmacy Services, Kaiser Permanente
  • Julia Logan, MD, MPH, Chief Clinical Director, California Public Employees’ Retirement System (CalPERS)
  • Mark McClellan, MD, PhD, Founding Director, Duke-Margolis Center for Health Policy, Duke University
  • Megan McIntyre, PharmD, Vice President, Pharmacy and Clinical Consulting, Premera Blue Cross
  • Ron Preblick, PharmD, Head, HEOR, US, General Medicines Market Access, Sanofi
  • Lindsay Rippelmeyer, PharmD, Senior Director, Supply Chain Finance, Express Scripts
  • Craig Roberts, PharmD, MBA, Vice President, Vaccines, Value and Implementation, Outcomes Research, Merck & Co., Inc.
  • Mark Shinmoto, PharmD, Vice President and Chief Pharmacy Officer, Ventegra
  • Sean D. Sullivan, PhD, Professor and Dean, University of Washington School of Pharmacy
  • Amir Abbas Tahami Monfared, MD, PhD, Head, Societal Value Platform and Evidence Development, Eisai, Inc.
  • Heidi C. Waters, PhD, MBA, Senior Director, Policy Research, Global Value & Real World Evidence, Otsuka Pharmaceutical
  • Kimberly Westrich, Chief Strategy Officer, National Pharmaceutical Council
  • Tiffany Westrich-Robertson, ICER Patient Council Co-Chair; CEO, International Foundation for Autoimmune & Autoinflammatory Arthritis (AiArthritis)
  • Jeff White, PharmD, Staff Vice President, Clinical Pharmacy Solutions, Elevance Health
  • Sarah Yoon, Director of Drug Information, Centene Pharmacy Services

        Methods Advisory Group

        ICER’s Methods Advisory Group (MAG) meets three times per year to provide guidance on ICER’s methods for health technology assessments and other evaluations. In the past few years, the MAG has helped to shape a data in-confidence policy, develop a pilot for a model transparency program, and comment on the process and methods for ICER’s report evaluating price increases for high impact drugs.

              • Alliance of Community Health Plans (ACHP)
              • California Public Employees’ Retirement System (CalPERS)
              • Centene Pharmacy Services
              • CVS Caremark
              • Eisai, Inc
              • Elevance Health
              • Express Scripts
              • Humana
              • Kaiser Permanente
              • Merck & Co.
              • National Pharmaceutical Council
              • Otsuka Pharmaceutical
              • Premera Blue Cross
              • Prime Therapeutics
              • Regeneron Pharmaceuticals, Inc.
              • Sanofi
              • Ventegra
              • Jeffrey A. Tice, MD, Department of Medicine, Division of General Internal Medicine, University of California